Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug ...

TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages ...

Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...

Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, ...

Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...

Jacob E. Berchuck, MD, highlights challenges in adopting liquid biopsy for PSMA expression and its potential to revolutionize precision medicine in prostate cancer.

PSMA PET/CT trial will scan up to 1000 men in the UKA new kind of scan that could be key to improving the treatment of high-risk prostate cancer is ...

Some urologists do get PET scans in this situation once the PSA is above 0.2 ng/mL, but I am not sure that you need it. Much depends on your PSA level when it's next checked in 6-12 months.

03 ng/mL to .09 ng/mL. My internist has suggested that I get a PET scan. Do you think this is necessary? — H.L. ANSWER: When the PSA level rises after radiation treatment for prostate cancer ...